Clinical Trial Update: A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] [EARLY_Phase 1]

View source ↗

Summary

Early-phase window-of-opportunity trial evaluating the combination of mirdametinib and vorinostat for NF1-associated, H3K27 trimethylation-deficient malignant p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor
• Neurofibromatosis Type

Drugs mentioned

• Mirdametinib (mirdametinib)
• Vorinostat (vorinostat)

Snippet

Sponsor: University of Minnesota | Conditions: Primary Malignant Peripheral Nerve Sheath Tumors | EARLY_Phase 1 | Status: RECRUITING